Can I use bacitracin and polymyxin B together?

Yes—they're often combined in single products. Combining them broadens coverage without antagonism. In fact, combination formulations (bacitracin + polymyxin B + neomycin) are among the most widely used over-the-counter topical antibiotics and provide empirical coverage of both gram-positive and gram-negative organisms.

Is polymyxin B stronger than bacitracin?

"Stronger" depends on the pathogen. Polymyxin B is bactericidal (kills bacteria) versus bacitracin's bacteriostatic effect, but for topical wound care in immunocompetent people, both work equally well clinically. Polymyxin B covers gram-negatives; bacitracin covers gram-positives. Neither is universally superior.

Which is safer for sensitive skin?

Both are safe topically. Bacitracin has slightly higher sensitization rates (~6% delayed hypersensitivity). Polymyxin B rarely causes contact dermatitis. If you have a history of antibiotic allergies, test either on a small area first. For severe eczema or compromised skin, neither is contraindicated, but patch testing is prudent.

Can bacteria develop resistance to these antibiotics?

Resistance to bacitracin and polymyxin B exists but is uncommon in community settings due to limited selective pressure from topical use. Polymyxin resistance is rare globally. Cross-resistance between them is minimal because they use different mechanisms, making combination therapy valuable.

Are these approved in all countries?

Both are FDA-approved in the US and Health Canada approved in Canada. The EMA has not authorized them as standalone agents in the EU, though some combination products may have approval in certain European markets. Check your local regulatory body for availability.

Bacitracin vs Polymyxin B: Key Differences & Uses

Bacitracin and Polymyxin B are both FDA-approved topical antibiotics used to prevent infection in minor cuts, burns, and scrapes. While they're often used together in combination products (like Neosporin), they work differently and have distinct antimicrobial profiles. Bacitracin targets gram-positive bacteria through cell wall inhibition, whereas Polymyxin B disrupts gram-negative bacterial membranes. Both have strong clinical evidence—Bacitracin has 40+ registered clinical trials, and Polymyxin B has 66+—but their coverage areas and resistance patterns differ meaningfully. Understanding these differences helps you choose the right option for specific wound types and infection risks.

What Is Bacitracin?

Bacitracin is a cyclic peptide antibiotic produced by the bacterium Bacillus subtilis. It was first isolated in 1945 and has been FDA-approved as a topical agent for decades. The compound works by inhibiting bacterial cell wall synthesis, specifically targeting the peptidoglycan cross-linking process. This mechanism makes it particularly effective against gram-positive bacteria, which rely heavily on robust cell walls for structural integrity.

Backitracin is bacteriostatic—it stops bacterial growth rather than killing bacteria outright. Clinical trials have demonstrated efficacy in wound care and infection prevention, with an impressive safety profile for topical use. The drug is typically formulated as an ointment at 500 units per gram and is available over-the-counter in most markets. Its spectrum covers Staphylococcus aureus, Streptococcus pyogenes, and other gram-positive pathogens, but gram-negative organisms are generally resistant.

What Is Polymyxin B?

Polymyxin B is a cyclic peptide antibiotic derived from Bacillus polymyxa. It operates via a fundamentally different mechanism: it disrupts the bacterial cell membrane (specifically the outer membrane of gram-negative bacteria) by acting as a cationic detergent. This creates pores and leakage, leading to bacterial cell death. Polymyxin B is bactericidal—it actively kills bacteria rather than merely inhibiting growth.

Research shows Polymyxin B covers gram-negative pathogens that resist bacitracin, including Pseudomonas aeruginosa, Escherichia coli, and Klebsiella species. With 66 registered clinical trials, the evidence base is substantial. Like bacitracin, it's formulated as a topical ointment (typically 10,000 units per gram) and is FDA-approved for wound care and infection prevention. However, polymyxin B has limited oral bioavailability and potential nephrotoxicity at systemic doses, which is why it's primarily used topically.

Key Differences: Spectrum & Mechanism

Antimicrobial Coverage

The most critical difference between these antibiotics is their target organism profiles. Bacitracin excels against gram-positive bacteria—the primary concern in everyday cuts and minor wounds. Polymyxin B dominates gram-negative coverage, making it the go-to choice when contamination with organisms like Pseudomonas is a risk (e.g., in water-related wounds or nosocomial settings).

This is why combination products exist: a bacitracin + polymyxin B formulation (often with neomycin added) covers both pathogenic categories in one application. Studies comparing combination topical antibiotics show broader empirical coverage than single-agent therapy.

Mechanism of Action

Bacitracin's cell wall inhibition is fundamentally different from Polymyxin B's membrane disruption. This means resistance mechanisms differ too. Bacteria resistant to bacitracin (via altered cell wall precursors) may remain susceptible to polymyxin B, and vice versa. This independence is clinically valuable when treating infections in patients with prior antibiotic exposure.

Bacteriostatic vs. Bactericidal

Bacitracin is bacteriostatic; Polymyxin B is bactericidal. In immunocompetent patients with minor wounds, this distinction matters less. But in immunocompromised or systemically ill patients, the more aggressive kill mechanism of polymyxin B can be advantageous. However, for topical use in routine wound care, both achieve clinical goals effectively.

Regulatory Status & Evidence

Both compounds have parallel regulatory pathways:

US: FDA-approved for topical wound care — both are over-the-counter
Canada: Health Canada approved for identical indications
EU: Neither is currently authorized by the EMA as a standalone topical agent, though combination products may have different status

The clinical trial base is robust for both. Bacitracin has 40+ registered clinical trials spanning decades of use, while Polymyxin B has 66+ trials, reflecting its broader systemic investigational history. Evidence grade for both is A—high-quality data supporting efficacy and safety.

Safety & Adverse Effects

Both antibiotics are exceptionally safe for topical use. Systemic absorption is minimal from intact skin, making serious toxicity rare. However, some clinical nuances exist:

Bacitracin: Rare contact dermatitis and sensitization have been reported. Approximately 6% of the population may develop delayed-type hypersensitivity. Cross-reactivity with other peptide antibiotics is possible.

Polymyxin B: Topical use is extremely safe. The historical nephrotoxicity and neurotoxicity concerns apply only to systemic (injectable) polymyxin B, not topical formulations. Local irritation is rare; contact sensitization is even less common than with bacitracin.

For compromised skin barriers (open wounds, burns), both are well-tolerated. Neither penetrates deeply or achieves systemic levels at typical topical doses.

Who Should Use Which?

Bacitracin Is Better For:

Minor cuts, scrapes, and abrasions with low infection risk
Suspected or confirmed gram-positive infections (e.g., S. aureus impetigo)
Patients with a history of polymyxin allergy (rare but documented)
Simple wound care in immunocompetent individuals
Cost-sensitive settings (bacitracin-only products are often cheaper)

Polymyxin B Is Better For:

Water-contaminated wounds (higher gram-negative risk)
Hospital or healthcare-associated wound care
Burns with pseudomonas risk
Patients with documented bacitracin sensitization
Immunocompromised patients where bactericidal activity is preferred
Situations requiring empirical gram-negative coverage

Combination Use:

For general consumer wound care, the bacitracin + polymyxin B + neomycin combination (Neosporin-type products) is sensible—it covers both major pathogenic categories without requiring diagnosis. Evidence supports this empirical approach for minor wounds.

Related Compounds & Glossary Context

If you're exploring topical antibiotics, understanding broader antimicrobial principles is helpful. Concepts like Accelerated Approval underpin how newer topical agents enter the market, and understanding 503B Outsourcing Facility regulations helps clarify how compounded antibiotic preparations are manufactured and regulated.

For those interested in peptide therapeutics more broadly, bacitracin and polymyxin B are classic examples of peptide antibiotics. Other peptides like Argireline (a cosmetic peptide) and ARA-290 (an erythropoietin analogue under investigation) represent the modern peptide landscape, though they operate in very different clinical domains.

Bottom Line

Bacitracin and Polymyxin B are complementary antibiotics with decades of safe, effective topical use. Bacitracin dominates for gram-positive coverage and routine minor wounds. Polymyxin B is superior for gram-negative organisms and higher-risk scenarios. In practice, many clinicians and consumers use combination formulations to maximize empirical coverage without needing to identify the specific pathogen. Both are FDA-approved, evidence-backed, and exceptionally safe for topical application. Your choice depends on wound type, contamination risk, and clinical context—not on one being universally "better" than the other.

Bacitracin vs Polymyxin B: Which Antibiotic Is Right?